KEY WORDS: Rheumatoid arthritis, Anti-TNF-agent, Switch, Etanercept, Infliximab, Adalimumab.
Anti-TNF-agents have been available for the treatment of rheumatoid arthritis (RA) since the year 2000. The first anti-TNF-agent available was infliximab. Anti-TFN-therapy has been shown to significantly improve the course of the disease, modifying the probability of remission in some patients and reducing and even stopping articular destruction [1] .
Today, three anti-TNF-agents are available for the treatment of RA: infliximab [2] , etanercept [3] and adalimumab [4] . The clinical effectiveness of anti-TNF-therapy in patients who are non-responders to methotrexate is between 60 and 70% American College of Rheumatology 20% [ACR] response [5] . In early RA, and before methotrexate treatment, effectiveness can reach 70% [6, 7] . Thus, at least 30% of patients do not respond to the first anti-TNF-treatment. Despite molecular differences [8] , these three anti-TNF-agents show similar degrees of effectiveness when combined with methotrexate [5, 9] .
Some studies have explored the effectiveness of treating patients who failed to respond to infliximab with etanercept, and vice versa [10] [11] [12] , showing an interest in changing from one anti-TNFagent to another when adverse events or inefficiencies occur.
To our knowledge, no studies have been conducted in which patients were treated successively with all three anti-TNF-agents. The objective of this study was to analyse the potential efficacy of a third anti-TNF-treatment after the first two had failed.
Patients and methods

Patients
Patients who had been diagnosed with RA, fulfilling the American College of Rheumatology (ACR) criteria [13] , and who had been treated with at least one anti-TNF-agent between July 2000 and August 2005 in the rheumatology department of a university hospital were identified by record review. The records of RA patients who had been treated with at least two anti-TNF-(infliximab, etanercept or adalimumab) agents were analysed. Eighty patients were identified following a review of 364 records. A standardized form was used to collect data on demographics, effectiveness and adverse events observed during the anti-TNFtherapy.
Evaluation
Demographic data included age, sex, rheumatoid factor, anticitrullinated protein antibodies (CCP) as detected by enzymelinked immunosorbent assay (ELISA) and disease duration. Previous DMARD therapy was recorded if known. Effectiveness criteria included tender and swollen joint counts (28-joint counts), morning stiffness (min), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Subjective data on global patient assessment were also available (rated from 0 to 100). The Disease Activity Score including 28 joints (DAS28) [14] was calculated on the basis of these criteria before the start of anti-TNF-therapy and again 3 months later. The change in DAS28 indicated the difference between the DAS28 before the anti-TNF-treatment and after 3 months of treatment. For patients who had stopped receiving the anti-TNF-treatment before the end of the 3-month interval, on account of the occurrence of adverse events, the change in DAS was calculated using the DAS28 at the moment the treatment was stopped. When the change in DAS was <1.2 at 3 months, or when the DAS 28 remained >5.1, treatment was considered to be ineffective. Safety criteria included laboratory data (complete blood count, Aspatate aminotransferase (AST), Alanine aminotransferase (ALT), albumin and creatinine) before anti-TNF-treatment and after switching to another anti-TNFagent, the number and severity of infusion reactions, infections, hospitalizations, other side-effects, and death.
Statistics
Data on the 80 patients were analysed using the SPSS program. Continuous variables were expressed as mean and standard deviation (S.D.). Owing to the small size of the samples, the Mann-Whitney test was used for intergroup comparisons. Statistical significance was defined as P<0.05.
Results
Characteristics of patients
One thousand two hundred and twenty-three RA patients were seen in a university hospital rheumatology department between July 2000 and August 2005. Infliximab was the first anti-TNFagent available in July 2000. Etanercept, which was initially available between 2000 and 2001, was finally authorized for prescription in February 2002 and adalimumab was available in February 2003. Of 1223 RA patients, 364 patients who had received anti-TNF-treatment were recorded. Two hundred and eighty-four (78%) of these had been treated with only one anti-TNF-agent and 80 patients (28%) had stopped receiving the first anti-TNF-agent due to adverse events or ineffectiveness before switching to another anti-TNF-therapy. Of these 80 patients, 55 (68%) continued being treated with the second anti-TNFagent and 25 had stopped receiving the treatment on account of adverse events or ineffectiveness, and switched to a third anti-TNF-agent. For 10 of the 80 patients, data were incomplete. Consequently, the records of 70 RA patients were assessed. Fifty of these patients had been treated with two anti-TNF-agents and 20 of them with all three. The characteristics of these 70 patients are shown in Table 1 . No difference was observed between the patients who had received two or three of the anti-TNF-agents as regards erosive disease, positivity for rheumatoid factor or anticitrullinated protein antibodies and mean number of DMARDs before anti-TNF-therapy. All of the 70 patients had active disease. Patients who had received two anti-TNF-agents had an initial DAS28 (before anti-TNF-treatment) of 5.97 (S.D. 0.93), and those who had received all three anti-TNF-agents had an initial score of 6.02 (S.D. 0.93).
Effectiveness of the second anti-TNF-agent in the cohort of 70 patients who had received two anti-TNF-agents Thirty-two patients had received infliximab first, 30 etanercept first and eight adalimumab first.
Thirty-two patients had switched from an antibody to a soluble receptor, with a good clinical response being observed in 45% of the patients. Thirty patients had switched from a soluble receptor to an antibody, again with a good clinical response being observed in 45% of the patients. Only eight patients had switched from an antibody to another antibody, with an efficiency score of 33%. Effectiveness of anti-TNF-therapy in the 20 patients who had received three anti-TNF-agents Effectiveness and adverse events with infliximab. In 12 of the 20 patients, anti-TNF-treatment began with infliximab as this was the first treatment available. DMARDs were associated with the anti-TNF-agent in 18 of the 20 patients (methotrexate in 15 cases and leflunomide in three cases). Infliximab was discontinued due to inadequate response in 65% of the patients. Of the eight patients who had stopped receiving the treatment due to adverse events, five had an allergic reaction, one had a pulmonary infection and one had a cutaneous reaction. The mean duration of treatment was 12.5 months (range 3-42).
Effectiveness and adverse events with etanercept. In six of the 20 patients, anti-TNF-treatment began with etanercept, whereas in 11 of the patients etanercept was second in the sequence of treatments. DMARDs (methotrexate) were associated with the anti-TNF-agent in 12 of the 20 patients. Etanercept was discontinued due to inadequate response in 85% of the patients. Three adverse events, one allergic reaction, one headache and one cutaneous reaction, were observed. One patient is still on the treatment. The mean duration of treatment was 5.36 months (range 3-8).
Effectiveness and adverse events with adalimumab. Adalimumab was the last in the sequence of treatment in 12 of the 20 patients. Only two of the patients began the anti-TNF-treatment with adalimumab. DMARDs were associated with the anti-TNF-agent in 12 of the 20 patients (methotrexate in eight cases and leflunomide in four cases). Adalimumab was discontinued due to inadequate response in 47% of the patients. Three adverse events (two allergies and one infection) were observed. Seven of the patients are still taking adalimumab. The mean duration of treatment for the nine patients who had stopped was 4.54 months (3) (4) (5) (6) (7) (8) .
Benefits of treatment with a third anti-TNF-agent after failure of one antibody and one soluble receptor. Of the 20 patients, seven showed a good response to the third anti-TNFagent and constituted group 1. In the 13 remaining patients, no response was observed and the treatment was discontinued due to lack of effectiveness. These 13 patients constituted group 2. When the characteristics of the two groups were compared, it was interesting to note that all of the group 1 patients save one had adverse events with one of the two initial anti-TNF-treatments. On the other hand, all except two of the group 2 patients had no adverse events but discontinued the anti-TNF-treatment (i.e. one anti-TNF-antibody and the soluble receptor) due to lack of effectiveness. In this group, switching to another anti-TNF-agent did not contribute to improving effectiveness. The number of adverse events occurring with the three anti-TNF-agents was compared between groups 1 and 2 and the difference was statistically significant (P ¼ 0.004). Moreover, in the group 2, in which RA was refractory to anti-TNF-therapy, the age of the patients was significantly higher than in group 1, although other parameters such as initial DAS28 and the number of DMARDs before anti-TNF-treatment were not different ( Table 2) .
Discussion
Three anti-TNF-agents, one soluble TNF-receptor (etanercept [3] ) and two anti-TNF-antibodies (infliximab [2] and adalimumab [4] ), are available for the treatment of RA. In this retrospective study we observed that patients who had failed to respond to the soluble TNF-receptor and to one of the two anti-TNF-antibodies on account of their inefficacy, and who had not shown side-effects, did not respond to the other anti-TNFantibody. On the other hand, most of the patients who had stopped receiving one of the first two anti-TNF-agents due to the occurrence of adverse events showed a good response to the third anti-TNF-agent. Moreover, patients in the anti-TNF--refractory group were older than those in the other group but did not differ, in terms of activity or previous treatment, from the group that responded to the third anti-TNF-treatment. To our knowledge, this is the first study that has assessed patients who were refractory to three anti-TNF-therapies.
When we analysed the entire population of RA patients who had received anti-TNF-treatment between 2000 and 2005, we observed that 68% of the patients who had switched from a first anti-TNF-agent to a second anti-TNF-agent continued the treatment for a mean follow-up of 11.81 months (S.D. 8.01).
This result is consistent with the literature as several studies have reported the benefits of using infliximab after etanercept [10, 11] or etanercept after infliximab [12, [15] [16] [17] [18] . When adalimumab (a second anti-TNF-antibody) was available, reports on its effectiveness after etanercept or infliximab were published [19, 20] . Most of the studies highlighted the benefits of switching from a soluble TNF-receptor to an anti-TNF-antibody or vice versa. In the literature, the switch from infliximab to etanercept provides an ACR 20 response in 64% of RA patients [11] and previous lack of effectiveness with etanercept does not predict lack of effectiveness with infliximab [10] . Two studies reported a switch from an anti-TNF-antibody (infliximab) to another anti-TNF-antibody (adalimumab) [19, 20] . The results showed a good level of efficacy, especially when infliximab was stopped for secondary failure. In our population, 68% of the patients who had switched from a first anti-TNF-agent to a second anti-TNF-agent continued with the treatment. Thus, most of the patients benefited from a change in anti-TNF-agents when they had initially been receiving only one.
Our population of anti-TNF--refractory patients is rather limited as it represents only 8.8% of all of the RA patients (284) treated with anti-TNF-agents in the last 5 yr. Although most of the data show that all three anti-TNF-agents are similarly effective [2] [3] [4] and that switching anti-TNF-agents is effective regardless of the molecule used [21] , our study shows that the third anti-TNF-agent was effective in only 35% of the patients. Moreover, when responders were compared with non-responders, we observed a lack of effectiveness without adverse events with the first two anti-TNF-agents in most of the non-responders, although all of the patients in the responders group had one adverse event with at least one of the first two anti-TNF-agents, suggesting that the previous anti-TNF-agent should have been effective in the absence of this complication.
In conclusion, RA patients who are refractory to all three anti-TNF-agents are rare. The ineffectiveness of two anti-TNFtreatments, one soluble receptor and one antibody, predict the ineffectiveness of the third anti-TNF-agent.
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